ThursdayJan 26, 2023 11:46 am

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled a virtual R&D Day for Feb. 28, 2023; the event is scheduled from 10 to 11:30 a.m. ET. The Cybin leadership team is slated to host the event, which will include an update on the company’s development pipeline of differentiated psychedelic-based therapeutics, including CYB003, which is being evaluated for the treatment of major depressive disorder, and CYB004, which is being evaluated for the treatment of generalized anxiety disorder. According to the announcement, the event will feature an interim readout from CYBN’s ongoing phase 1/2a…

Continue Reading

ThursdayJan 26, 2023 11:22 am

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Reports on Special Shareholder Meeting, Announces Key New Hires

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is releasing results from its reconvened Special Meeting of Stockholders. The meeting, which was held on Jan. 25, 2023, included several proxy proposals on the agenda; MULN is reporting that all proposals were approved. According to the announcement, the company has no current plans to effect a reverse split. In addition, the company has until March 6, 2023, to meet the $1 minimum bid requirement established by NASDAQ. Based on the report, if that share price isn’t met, MULN will seek an extension from NASDAQ to meet the required threshold, which would…

Continue Reading

ThursdayJan 26, 2023 10:52 am

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Year-End Webcast Review

Flora Growth (NASDAQ: FLGC), a leading outdoor grower, manufacturer and distributor of cannabis products and brands worldwide, has scheduled a webcast to provide an overview of the company’s operational milestones achieved in 2022. The year-end review is slated for Jan. 30, 2023, and will begin at 4:30 p.m. ET. The webinar, which will be prerecorded, will feature Flora Growth chair and CEO Luis Merchan, who will discuss the company’s 2022 operational performance; Merchan will also talk about the company’s 2023 revenue guidance. Those who attend the event will receive a recording of the webcast after it is concluded; a recording…

Continue Reading

TuesdayJan 24, 2023 11:57 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses ‘Lifeblood’ of Phase 2 Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers in the brain and central nervous system, is enrolling patients in a phase 2 trial to evaluate the efficacy of its flagship drug candidate. The potentially pivotal trial will evaluate Berubicin for the treatment of glioblastoma multiforme (“GBM”), an aggressive brain tumor with an average overall survival rate of only 10-12 months. The company’s Chief Executive Officer John Climaco recently participated in the Virtual Investor “Ask the CEO” Event and discussed that enrollment in the trial was approaching 70 patients against a…

Continue Reading

TuesdayJan 24, 2023 11:06 am

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Working Toward Global Leadership in CBD Space

Flora (NASDAQ: FLGC) has transitioned from the development stage to a full-scale international distributor with operations in over 12 countries worldwide, achieved under Luis Merchan’s tenure as CEO. “Merchan has also spearheaded several mergers and acquisitions, most notably JustCBD and Vessel Brand, which have since set the company up for rapid growth. Flora also secured $34.5 million in financing and signed deals with key retail distributors such as Tropi, a Colombia-based distributor, Walmart and Macy’s. The company also completed its first import of CBD-containing food and beverage products into the United States from Colombia under its Mambe brand. It has…

Continue Reading

MondayJan 23, 2023 1:26 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pharmaceutical Expert as New Strategic Advisor

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has a new strategic advisor. The company announced that Julian Gangolli, the former president of GW Pharmaceuticals USA, has joined Lexaria as a strategic advisor. During his time at GW Pharmaceuticals, Gangolli managed US Food and Drug Administration approval of Epidiolex(R), the only pure cannabidiol (“CBD”) drug ever approved by the agency; he also oversaw the commercialization of the drug in the United States, which ultimately led to Jazz Pharmaceuticals acquiring GW Pharmaceuticals in a $7.2 billion transaction. In addition to his work at GW Pharmaceuticals, Gangolli served as North…

Continue Reading

MondayJan 23, 2023 12:59 pm

TinyGemsBreaks – QSAM Biosciences Inc. (QSAM) to Present at Emerging Growth Conference

QSAM Biosciences (OTCQB: QSAM) is developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases and conditions. The company today announced that it has been invited to present at the Emerging Growth Conference at 10:15 a.m. ET on Wednesday, Jan. 25, 2023. Leading QSAM’s presentation will be the company’s CEO Douglas Baum and other executive officers, who may subsequently open the floor for questions. Interested parties should visit https://ibn.fm/P2xIR to register to attend the conference and receive any updates. An archived webcast will be made available on EmergingGrowth.com and on the Emerging Growth YouTube…

Continue Reading

MondayJan 23, 2023 10:15 am

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Unveils Streamlined, Automated Carrier Onboarding Process

Freight Technologies (NASDAQ: FRGT), a technology company whose custom-developed Fr8App, an industry-leading freight-matching platform powered by AI and machine-learning, offers a real-time portal for B2B cross-border shipping and domestic shipping within the USMCA region, has announced a new, automated and effortless carrier onboarding process. The new process, states the company, makes it even easier qualified carriers to sign up and move loads with Fr8App. The announcement noted that qualified carriers who sign up on the Fr8App platform, can approved and unlock all the platform options in only minutes; users simply follow step-by-step instructions that are provided. The new streamlined process…

Continue Reading

FridayJan 20, 2023 12:25 pm

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Reaches Pivotal Milestone to Advance ADI (TM) Technology

Aditxt (NASDAQ: ADTX) recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune Inc., and appointed Joachim-Friedrich Kapp, MD, Ph.D, a 30-year veteran of the pharmaceutical industry, as its chairman and CEO. “Dr. Kapp will be tasked with leading and developing the ADI(TM) immune modulation technology and ADI(TM)-100, Aditxt’s unique and potent antigen-specific immunotherapeutic technology drug candidate, toward clinical trials… Short for Apoptotic DNA Immunotherapy(TM), ADI(TM) is a nucleic acid-based technology platform that utilizes a novel antigen-specific approach to induce immune tolerance by mimicking the way the body naturally induces tolerance to its own tissues. The technology, the company…

Continue Reading

FridayJan 20, 2023 10:41 am

TinyGemsBreaks — Cepton Inc. (NASDAQ: CPTN) Completed $100M Koito Manufacturing Investment

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, has closed its previously announced $100 million investment with Koito Manufacturing Co. Ltd.; Koito is a long-term automotive Tier 1 partner and current CPTN shareholder. The transaction closed on Jan. 19, 2023, and was in the form of convertible preferred stock. Cepton’s stockholders approved the move at a special meeting held on Jan. 11, 2023. The investment is convertible into shares of Cepton’s common stock at an initial conversion price of $2.585 per share; the conversion date begins on the first anniversary of the issue date. “We’re happy…

Continue Reading

Contact us: (310) 299-1717